Bio Sequence

CAR-T Core Functional Component Sequence Retrieval Strategy

27 September 2023
3 min read

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Once equipped with a CAR construct, T cells act as living drugs and recognize and eliminate the target tumor cells in an MHC-independent manner. 

CARs are synthetic immune receptors that connect a single-chain variable fragment (scFv), derived from a monoclonal antibody to T cell signaling domains to eradicate tumor cells independent of the major histocompatibility complex (MHC).

Once equipped with a CAR, T cells, known as CAR-T cells, act as living drugs and recognize and eliminate the target tumor cells. The conventional CAR structure consists of three modular components: the ectodomain, the transmembrane domain, and the endodomain, each of which has specific components and functions and thus the potential to be optimized.

An exemplification using Tisagenlecleucel demonstrates the approach of performing sequence retrieval for each individual region, as well as searching for the overall relevant sequence through a combination of different fragments.

I. Fragment Search

Creating a complimentary account in the Patsnap Bio Sequence Database is necessary to initiate the fragment search process. Subsequently, on the database's homepage, the complete sequence of Tisagenlecleucel should be entered into the fragment search function. On the right-hand side, the option to select multiple segments should be chosen (up to 10 segments are currently supported). In this case, the starting and ending positions of three segments, namely Hinge, Transmembrane, and Intracellular, should be inputted separately. By clicking on the "Search" button, the related sequence results for the three core functional components of Tisagenlecleucel will be obtained.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

II. Combined Search

The combination search feature, situated on the homepage of the Bio database, permits simultaneous searches of multiple sequences, based on the core functional components of CAR-T therapy, including the antigen recognition region, hinge region, transmembrane region, and intracellular structural domain. The three segments of tisagenlecleucel discussed previously – Hinge, Transmembrane, and Intracellular – should be entered separately into the search box (up to 6 segment combinations are currently supported). Subsequently, by clicking "Search," a heatmap illustrating the publicly available patents that disclose the combination of the three sequences will be displayed. Further investigation into the details of these patents is possible.

图形用户界面, 应用程序

描述已自动生成

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

The FDA expedites reviewing Merck's request to use KEYTRUDA®, alongside chemoradiotherapy, for cervical cancer treatment
Latest Hotspot
3 min read
The FDA expedites reviewing Merck's request to use KEYTRUDA®, alongside chemoradiotherapy, for cervical cancer treatment
27 September 2023
Merck has reported that the U.S. FDA is conducting a priority analysis on a fresh sBLA petitioning for authorization of KEYTRUDA, Merck’s anti-PD-1 treatment.
Read →
Advances in Clinical Research on Cholinesterase Inhibitors
Advances in Clinical Research on Cholinesterase Inhibitors
27 September 2023
Cholinesterase is a class of glycoprotein that is present in the body in various isoenzyme forms. It can be generally divided into true cholinesterase and pseudocholinesterase.
Read →
The Menarini Group's ORSERDU® (Elacestrant) has received approval from the EC for breast cancer
Latest Hotspot
3 min read
The Menarini Group's ORSERDU® (Elacestrant) has received approval from the EC for breast cancer
27 September 2023
The Menarini Group,together with their fully owned subsidiary Stemline Therapeutics Inc., declared that ORSERDU® (elacestrant) has received authorisation from the European Commission.
Read →
Dexmethylphenidate Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Dexmethylphenidate Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
30 September 2023
This article summarized the latest R&D progress of Dexmethylphenidate Hydrochloride, the Mechanism of Action for Dexmethylphenidate Hydrochloride, and the drug target R&D trends for Dexmethylphenidate Hydrochloride.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.